Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; matters affecting infusion therapies. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Duration: April 7, 2017
to
present
General Issues: Health Issues , Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Budget/Appropriations
Spending: about $840,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS)
Related Foreign Entities:
Mitsubishi Tanabe Pharma Corporation (Chuo-ku, Osaka , JPN); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Karina Lynch Staff, Senate Special Committee on Aging; Staff, Senate Committee on Govt Affairs; Senate Committees on Aging and Govt Affairs
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs.
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs
Cheryl Jaeger Shd Employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
Shd employee, Ofc of the Speaker 7 Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox
Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C;
Sr LA to Rep. Cox
Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C;
Sr LA to Rep. Cox
Andrew Jones Legislative Counsel, Rep Hinojosa; Legislative Director and Counsel, Rep Lujan
Leg Counsel, Rep Hinojosa; Leg Director and Counsel, Rep Lujan
George Olsen n/a
David Starr n/a
Nicole Bertsch n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on April 18.
Original Filing: 301553042.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; matters affecting infusion therapies. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Jan. 17.
Original Filing: 301526172.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; matters affecting infusion therapies. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Oct. 17, 2023.
Original Filing: 301502153.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on July 14, 2023.
Original Filing: 301476341.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on April 19, 2023.
Original Filing: 301457641.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439443.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2022
In Q3, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Oct. 19, 2022.
Original Filing: 301409778.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; Legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program. Legislation to improve access to treatments for ALS. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, "Inflation Reduction Act of 2022" (PL 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program. Legislation to improve access to treatments for ALS. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, "Inflation Reduction Act of 2022" (PL 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 7667, the Food and Drug Amendments of 2022 and S.4348, the FDA Safety and Landmark Act. H.R.6833 Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180), including FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2022
In Q2, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on July 20, 2022.
Original Filing: 301389793.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program, Buy America requirements; and imposition of most favored nation pricing on drugs. Legislation to improve access to treatments for ALS. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 7667, the Food and Drug Amendments of 2022 and S.4348, the FDA Safety and Landmark Advancements Act (FDSLA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2022
In Q1, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on April 19, 2022.
Original Filing: 301360813.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program, Buy America requirements; and imposition of most favored nation pricing on drugs. Legislation to improve access to treatments for ALS. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2021
In Q4, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Jan. 19, 2022.
Original Filing: 301327251.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program, Buy America requirements; and imposition of most favored nation pricing on drugs. Legislation to improve access to treatments for ALS. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308979.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program, Buy America requirements; and imposition of most favored nation pricing on drugs. Legislation to improve access to treatments for ALS. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and subsequent proposals; H.R. 19, Lower Costs, More Cures Act of 2021; and H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on July 20, 2021.
Original Filing: 301285479.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; the 340B drug discount program, Buy America requirements; and imposition of most favored nation pricing on drugs. Legislation to improve access to treatments for ALS. President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Legislation concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Budget reconciliation and President Bidens FY 2022 Budget Proposal, The American Jobs Plan, and The American Families Plan.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on April 19, 2021.
Original Filing: 301258153.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. Legislation to improve access to treatments for ALS. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Budget reconciliation and the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234901.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3; Lower Drug Costs Now Act of 2019; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 1407/S.578, ALS Disability Insurance Access Act; and H.R. 7071, Accelerate Access to Critical Therapies for ALS Act. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act. H.R. 133, Consolidated Appropriations Act, 2021, Pub. L. No. 116-260.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Oct. 19, 2020.
Original Filing: 301214799.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3; Lower Drug Costs Now Act of 2019; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act"). Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. H.R. 1407/S.578, ALS Disability Insurance Access Act; and H.R. 7071, Accelerate Access to Critical Therapies for ALS Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on July 17, 2020.
Original Filing: 301190404.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3; Lower Drug Costs Now Act of 2019; Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act").
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019. Policies impacting the U.S. response to the COVID-19 pandemic including H.R. 604, the Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No. 116-123; H.R. 6201, Families First Coronavirus Response Act, Public Law No. 116-127; H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law No. 116-136; and H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301173583.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Implementation of the Right to Try Act of 2017. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; S.3548/H.R. 748, Coronavirus Aid, Relief, and Economic Security Act; H.R. 6201, Families First Coronavirus Response Act; and H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals. S 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Jan. 16, 2020.
Original Filing: 301107403.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Implementation of the Right to Try Act of 2017. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; H.R. 1865, Further Consolidated Appropriations Act 2020.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals. S 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Oct. 17, 2019.
Original Filing: 301067638.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Implementation of the Right to Try Act of 2017. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals. S 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on July 17, 2019.
Original Filing: 301047254.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Implementation of the Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals under Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to pharmaceuticals; payment policies for drugs under Medicare Part B; Coverage of drugs under Part B and Part D.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2019
In Q1, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301035050.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; Implementation of the Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals under Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Jan. 18, 2019.
Original Filing: 301008858.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; Implementation of the Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to pharmaceuticals; payment policies for drugs under Medicare Part B.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Oct. 18, 2018.
Original Filing: 300988438.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; Implementation of the Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to pharmaceuticals.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on July 18, 2018.
Original Filing: 300967672.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300958391.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Jan. 12, 2018.
Original Filing: 300923218.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act; H.R. 2430, S. 934, FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs/Medicaid
3rd Quarter, 2017
In Q3, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on Oct. 18, 2017.
Original Filing: 300906509.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act; H.R. 2430, S. 934, FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs/Medicaid
2nd Quarter, 2017
In Q2, Williams and Jensen, PLLC lobbied for MT Pharma America, Inc. , earning $30,000. The report was filed on July 12, 2017.
Original Filing: 300883598.xml
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act; H.R. 2430, S. 934, FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs/Medicaid
2nd Quarter, 2017
Williams and Jensen, PLLC filed a lobbying registration on May 17, 2017 to represent MT Pharma America, Inc., effective April 7, 2017.
Original Filing: 300880308.xml
Issue(s) they said they’d lobby about: Matter affecting access to and pricing of pharmaceutical; matter affecting the Orphan Drug Act. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...